The role of omega-3 polyunsaturated fatty acids in cardiovascular health

Alternative Therapies in Health and Medicine

Volumn 19, Issue SUPPL.1, 2013, Pages 26-30

  Barrett, Sara Jean ^a  

^a Alternative Solutions for Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID;

CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; HEALTH PROMOTION; HEALTH STATUS; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; FATTY ACIDS, OMEGA-3; HEALTH PROMOTION; HEALTH STATUS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884217008     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper HH, ed. Advanced Nutrition Research. New York, NY: Plenum Press; 1980:1-32.
2. Simopoulos AP. Evolutionary aspects of omega-3 fatty acids in the food supply. Prostaglandins Leukot Essent Fatty Acids. 1999;60(5-6):421-429.
3. Lands WE. Biochemistry and physiology of n-3 fatty acids. FASEB J. 1992;6(8):2530-2536.
4. Simopoulous AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70(3)(suppl):560S-569S.
5. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb. 1994;14(11):1829-1836.
6. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dosedependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J. 2011;161(5):915. e1-9.
7. von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest. 1985;76(4):1626-1631.
8. von Schacky C. Prophylaxis of atherosclerosis with marine omega-3 fatty acids: a comprehensive strategy. Ann Intern Med. 1987;107(6):890-899.
9. Phang M, Lincz L, Seldon M, Garg ML. Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects. J Nutr Biochem. 2012;23(9):1128-1133.
10. Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Unda A. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol. 2001;31(7):1696-1702.
11. Wei MY, Jacobson TA. Effects of eiocosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13(6):474-483.
12. Bernstein AM, Ding EL, Willett WC, Rimm EB. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr. 2012;142(1):99-104.
13. Dayspring TD. Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters. Int J Womens Health. March 2011;3:87-97.
14. Morgan DR, Dixon LJ, Hanratty CG, et al. Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure. Am J Cardiol. 2006;97(4):547-551.
15. O'Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol. 2006;97(8):1127-1130.
16. Amano T, Matsubara T, Uetani T, et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis. 2011;218(1):110-116.
17. Kashiyama T, Ueda Y, Nemoto T, et al. Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio. Circ J. 2011;75(10):2432-2438.
18. Cao J, Schwichtenberg KA, Hanson NQ, Tsai MY. Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem. 2006;52(12):2265-2272.
19. Harris WS, Sands SA, Windsor SL, et al. Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation. 2004;110(12):1645-1649.
20. Sun Q, Ma J, Campos H, Hankinson SE, Hu FB. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. J Clin Nutr. 2007;86(1):74-81.
21. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274(17):1363-1367.
22. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis. 2008;197(2):821-828.
23. Harris WS, von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212-220.
24. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287(14):1815-1821.
25. Iso H, Kobayashi M, Ishihara J, et al; JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-based (JPHC) study cohort 1. Circulation. 2006;113(2):195-202.
26. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2(8666):757-761.
27. fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-455.
28. De Caterina R, Madonna R, Zucchi R, La Rovere MT. Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. Am Heart J. 2003;146(3):420-430.
29. Wang C, Harris WS, Chung M, et al. n-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary-and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84(1):5-17.
30. Mozaffarian D, Prineas RJ, Stein PK, Siscovick DS. Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans. J Am Coll Cardiol. 2006;48(3):478-484.
31. Marchioli R, Barzi F, Bomba E, et al; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio (GISSI)-Prevenzione. Circulation. 2002;105(16):1897-1903.
32. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol. 2006;98(4A):50i-60i.
33. Leaf A, Albert CM, Josephson M, et al; Fatty Acid Antiarrhythmia Trial Investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation. 2005;112(18):2762-2768.
34. von Schacky C. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both? Curr Opin Clin Nutr Metab Care. 2008;11(2):94-99.
35. Calo L, Bianconi L, Colivicchi F, et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45(10):1723-1728.
36. Heidt MC, Vician M, Stracke SK, et al. Beneficial effects of intravenously administered n-3 fatty acids for the prevention of atrial fibrillation after coronary bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg. 2009;57(5):276-280.
37. He Z, Yang L, Tian J, Yang K, Wu J, Yao Y. Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. Can J Cardiol. 2013;29(2):196-203.
38. Harris WS, Gonzales M, Laney N, Sastre A, Borkon AM. Effects of omega-3 fatty acids on heart rate in cardiac transplant recipients. Am J Cardiol. 2006;98(10):1393-1395.
39. Holm T, Andreassen AK, Aukrust P, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant patients. Eur Heart J. 2002;22(5):428-436.
40. Andreassen A, Hartmann A, Offstad J, Geiran O, Kvernebo K, Simonsen S. Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. J Am Coll Cardiol. 1997;29(6):1324-1331.
41. Patel JV, Tracey I, Hughes EA, Lip GY. Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences or unfulfilled promise? J Thromb Haemost. 2010;8(10):2095-2104.
42. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312(19):1205-1209.
43. Kwak SM, Myung SK, Lee YJ, Seo HG; Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a metaanalysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172(9):686-694.
44. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024-1033.
45. de Lorgeril M, Salen P, Defaye P, Rabaeus M. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med. January 2013;11:5.
46. Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D. Effects of n-3 fatty acids on major cardiovascular events in statin users and nonusers with a history of myocardial infarction. Eur Heart J. 2012;33(13):1582-1588.
47. Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation. 1995;91(3):645-655.
48. Houston MC. Role of mercury toxicity in hypertension, cardiovascular disease, and stroke. J Clin Hypertens (Greenwich). 2011;13(8):621-627.
49. Virtanen JK, Voutilainen S, Rissanen TH, et al. Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland. Arterioscler Thromb Vasc Biol. 2005;25(1):228-233.
50. Virtanen JK, Laukkanen JA, Mursu J, Voutilainen S, Tuomainen TP. Serum longchain n-3 polyunsaturated fatty acids, mercury, and risk of sudden cardiac death in men: a prospective population-based study. PLoS One. 2012;7(7):e41046.
51. Food and Drug Administration; US Department of Health and Human Services. Substances affirmed as generally recognized as safe: menhaden oil. CFR Part 184. http://www.gpo.gov/fdsys/pkg/FR-1997-06-05/pdf/97-14683.pdf. Published June 5, 1997. Accessed April 11, 2013.
52. US Department of Health and Human Services. Omega-3 supplements: an introduction. National Center for Complementary and Alternative Medicine Web site. http://nccam.nih.gov/health/omega3/introduction.htm. Published July 2009. Updated November 2012. Accessed April 11, 2013
53. Guallar E, Sanz-Gallardo MI, van't Veer P, et al; Heavy Metals and Myocardial Infarction Study Group. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med. 2002;347(22):1747-1754.
54. Jacobs MN, Santillo D, Johnston PA, Wyatt CL, French MC. Organochlorine residues in fish oil dietary supplements: comparison with industrial grade oils. Chemosphere. 1998;37(9-12):1709-1721.
55. Hilbert G, Lillemark L, Balchen S, Hojskov CS. Reduction of organochlorine contaminants from fish oil during refining. Chemosphere. 1998;37(7):1241-1252.
56. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr. 1997;65(5)(suppl):1687S-1698S.
57. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99(6A):35C-43C.
58. Raitt MH, Conner WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293(23):2884-2891.
59. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertryglyceridaemia. Heart. 2001;85(5):544-548.
60. Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006;98(4A):34i-38i.
61. Nordoy A, Bonaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of simvastatin and omega-3 fatty acids in plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia. J Intern Med. 1998;243(2):163-170.
62. Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-332.
63. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-2757.
64. Guidelines for secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. American College of Cardiology Web site. http://cardiocompass.cardiosource.org/cc2/openCont1?smID=929. Accessed April 2, 2013.
65. World Health Organization. Diet, Nutrition and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation. Geneva, Switzerland: World Health Organization; 2003.
66. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. December 2005;91(suppl 5):v1-v52.
67. Reiner Z, Catapano AL, De Backer G, et al; The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32(14):1769-1818.